Y-Mabs Therapeutics Accounts Payable

Y-Mabs Therapeutics (YMAB) currently reports a accounts payable of $7.6M as of June 2025. That compares with $10M in the prior-year period — down 25.7% year over year. Use the charts on this page to explore Y-Mabs Therapeutics's accounts payable history and peer comparisons.

Y-Mabs Therapeutics's accounts payable decreased from $10M to $7.6M — a 25.7% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Y-Mabs Therapeutics reported $7.6M in accounts payable as of June 2025. That compares with $10M in the prior-year period — down 25.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $7.6M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Y-Mabs Therapeutics, and consider following YMAB for alerts when major investors trade the stock.

Y-Mabs Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $7.6M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing YMAB with unrelated industries.